Year: 2017

Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers

Enterome to Move its Research Laboratories to Genopole, France’s First Biocluster

Enterome appoints Mary Thistle to its Board of Directors

Enterome and Nestlé Health Sciences launch new diagnostics company

Enterome starts Phase I clinical trial with its lead candidate EB8018 to treat Crohn’s disease